title: Frequency and effective treatment of ulcers and sinuses in cases of tuberculous cervical lymphadenitis.
abstract: OBJECTIVE
  To investigate the frequency and effective treatment of ulcers and sinuses in cases of tuberculous cervical lymphadenitis (TCL).
  
  
  METHODS
  Observational cross-sectional study.
  
  
  METHODS
  Department of ENT, Head and Neck Surgery of Tribhuvan University Teaching Hospital (TUTH), Kathmandu, Nepal, during the period of two years from March, 2000 to February, 2002.
  
  
  METHODS
  A hundred cases of histopathologically confirmed cases of tuberculous cervical lymphadenitis of more than six weeks of duration were included in the study. Overall frequency of the complication as well as the efficacy of treatment regime was considered.
  
  
  RESULTS
  Out of 100 patients, 8 (8%) were found to develop ulcers and/or sinuses during the process of development of TCL which were effectively treated (100% cure rate). Mode of treatment was surgical excision of ulcers/sinuses along with affected underlying lymph nodes, followed by short course of anti-tubercular chemotherapy. Not a single case recurred during their follow-up period.
  
  
  CONCLUSIONS
  In this series there was a low frequency of formation of ulcers/sinuses during the process of development of TCL. Surgical excision of ulcers/sinuses along with affected underlying lymph nodes, followed by short course of anti-tubercular chemotherapy is the effective methods of their treatment.
authors.affiliation: Department of ENT, Head and Neck Surgery, Tribhuvan University, Institute of Medicine, Teaching Hospital, Post Box No: 3578, Kathmandu. Nepal. dkbaskota@yahoo.com
authors.forename: Dharma Kanta
authors.initials: DK
authors.lastname: Baskota
authors.forename: Rakesh
authors.initials: R
authors.lastname: Prasad
authors.forename: Bimal Kumar
authors.initials: BK
authors.lastname: Sinha
authors.forename: Ram Chhaya Man
authors.initials: RC
authors.lastname: Amatya
mesh_terms: D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D002648:Child; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D003906:Developing Countries; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008199:Lymphadenitis / Q000150:complications / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D009333:Neck; D010154:Pakistan; D010254:Paranasal Sinus Diseases / Q000188:drug therapy* / Q000209:etiology* / Q000382:microbiology; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014388:Tuberculosis, Lymph Node / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D014456:Ulcer / Q000188:drug therapy* / Q000209:etiology* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents